Crinetics Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.7M | $1.0M | $4.0M | $0 | $0 |
| Cost of revenue | $1.1M | $0 | $0 | — | — |
| Selling, general & administrative | $191.3M | $99.7M | $58.1M | — | — |
| Research and development | $332.1M | $240.2M | $168.5M | $130.2M | $84.3M |
| Operating expenses | — | $339.9M | $226.6M | $172.6M | $108.8M |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M | -$107.7M |
| Pretax income | -$465.1M | -$297.9M | -$209.3M | -$163.9M | -$107.6M |
| Income tax expense | $180,000 | $0 | $0 | $0 | $0 |
| Net income | -$465.3M | -$298.4M | -$214.5M | -$163.9M | -$107.6M |
| Balance Sheet | |||||
| Cash and equivalents | $101.5M | $264.5M | $54.9M | $32.7M | $200.7M |
| Current assets | $1.0B | $1.4B | $574.2M | $345.2M | $344.7M |
| Total assets | $1.1B | $1.4B | $635.4M | $352.2M | $351.0M |
| Current liabilities | $85.1M | $59.7M | $43.9M | $27.7M | $16.0M |
| Total liabilities | $134.2M | $109.8M | $96.2M | $35.8M | $19.1M |
| Stockholders' equity | $992.1M | $1.3B | $539.1M | $316.3M | $331.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$377.9M | -$230.2M | -$168.6M | -$115.2M | -$88.6M |
| Depreciation and amortization | $3.9M | $2.8M | $1.1M | $1.0M | $900,000 |
| Stock-based compensation | $91.0M | $69.4M | $40.9M | $28.3M | $17.4M |
| Capital expenditure | $5.8M | $3.8M | $4.7M | $1.7M | $436,000 |
| Free cash flow | -$383.7M | -$234.0M | -$173.3M | -$116.9M | -$89.0M |
| Impairments | — | $0 | $0 | $0 | $0 |
Shares outstanding 105.4M · Free float 90.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.